Nicolas Bardonnet – General Manager, Promega France
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
With a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions to life scientists in academic, industrial and government settings. Founded in 1978 byWilliam Linton in Madison, Wisconsin, Promega has branches in 16 countries and more than 50 global distributors serving 100 countries. They have eight European branches. Promega has been present in France since 1982 and are responsible for operations in Greece, Egypt as well as North Africa and French speaking African countries. France hosts both their European application centre as well as the European training centre, which offers a wide range of courses in molecular biology, cell biology, proteomics and genetic identity.
Contact
Address: 24 Chemin des Verrières, 69260 Charbonnières-les-Bains, France
Tel: +33 4 37 22 63 48
Web: france.promega.com
Facebook: https://www.facebook.com/promegafrance
Twitter (@PromegaFR): https://twitter.com/PromegaFR
LinkedIn: https://www.linkedin.com/company/promega
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell…
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the…
Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and…
ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a…
At a time when France’s healthcare landscape is being reshaped by regulatory change, market pressure, and shifting patient expectations, Fabrice Ruggeri, Country Manager of Organon France, is steering the affiliate…
Under the leadership of Nicolas Bardonnet, Promega France has expanded its role from a broad portfolio provider to a more collaborative partner supporting key human health applications. Bardonnet has integrated…
Benta Lyon is reshaping its industrial footprint with unusual speed, combining a fast-growing CDMO platform, an expanding French made generics portfolio and new sterile capabilities that will anchor its next…
argenx has moved from an antibody engineering start-up to one of Europe’s most closely-watched biotechs, advancing a pipeline that spans multiple autoimmune diseases. In this interview, François Rauch reflects on…
With over 25 years of experience at the crossroads of science and business, Pascal Villemagne, CEO of SEQENS, shares his vision for steering the French CDMO into a new era…
France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and…
Jerome Estampes, CFO and interim CEO of Guerbet France, discusses his journey from joining the company in 2019 through to his current dual role, navigating the challenges of generic competition,…
Alexion France is entering a pivotal phase as the rare-disease landscape becomes more competitive, more data driven and increasingly shaped by early access and clinical-trial performance. In this interview, Celine…
See our Cookie Privacy Policy Here
